Dr. John K. Joseph, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 535 E Crescent Ave, Histopathology Services, Llc, Ramsey, NJ 07446 Phone: 201-661-7280 Fax: 201-661-7297 |
Dr. Zach Liu, MD Pathology - Hematology Medicare: Accepting Medicare Assignments Practice Location: 535 E Crescent Ave, C/o Histopathology Services, Llc, Ramsey, NJ 07446 Phone: 201-661-7280 Fax: 201-661-7297 |
Dr. Schuyler Newman, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 535 E Crescent Ave, C/o Histopathology Services, Llc, Ramsey, NJ 07446 Phone: 201-661-7280 Fax: 201-661-7297 |
Marius J-m Ilario, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 535 E Crescent Ave, C/o Histopathology Services, Llc, Ramsey, NJ 07446 Phone: 201-661-7280 Fax: 201-661-7297 |
News Archive
Santhera Pharmaceuticals and Ipsen today announced a license agreement for the development and commercialization of fipamezole (antagonist of the adrenergic alpha-2 receptor) for territories outside of North America and Japan. This first-in-class compound is currently under investigation for the treatment of levodopa-induced dyskinesia in Parkinson's Disease.
HealthPort, an industry leader in health information technology announced today, the availability of a comprehensive software and services solution to manage audits in healthcare, including RAC, MIC, MAC and other government contractors as well as commercial plan and internal coding and compliance audits.
Wu and colleagues studied data for patients under age 65 with at least one diagnosis of Interstitial Cystitis (IC) from a de-identified administrative database of 2 million beneficiaries that included medical, drug and disability claims for 1999-2002.
On December 2, 2006, FDA was notified that Pfizer will suspend a large, Phase 3 trial evaluating the investigational cardiovascular therapy torceptrapib/atorvastatin (T/A) due to an increased rate of mortality (death) in patients receiving the combination compared to those receiving atorvastatin alone.
› Verified 6 days ago